Nxc 201 News Today

The CAR T-cell therapy NXC-201 has received orphan drug designation by the European Commission for patients with multiple myeloma.

Faculty offer insights on the NEXICART-1 phase 1 clinical trial investigating the safety and efficacy of NXC-201 in patients with AL amyloidosis and discuss potential clinical implications on the study’s findings.

Heather Landau, MD, invites panelists to provide their insights on the future outlook for the treatment of AL amyloidosis.

NXC-201 has received orphan drug designation from the European Commission for use in patients with amyloid light-chain amyloidosis.

Vaishali Sanchorawala, MD, provides insights on the pooled safety analysis of data from phase 1 to 3 trials, including PRONTO and VITAL, which investigated the use of birtamimab in patients with light chain (AL) amyloidosis.

A panel of expert oncologists discuss the underlying rationale and potential role for CAR T therapy in patients with AL amyloidosis.

A panel of expert oncologists explore novel therapies using monoclonal antibodies designed to target amyloid deposit, highlighting key data from the VITAL study.

A panel of expert oncologists explore the ongoing AFFIRM-AL trial, examining birtamimab in patients diagnosed with Mayo stage IV AL amyloidosis.

A panel of expert oncologists discuss the importance of cardiac staging for patients with AL amyloidosis and it’s role in guiding overall treatment.

Faculty delve into potential challenges related to the management of patients with AL amyloidosis and cardiac involvement, discussing the associated prognostic implications.